Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.
Sunmax Biotechnology Co Ltd - Asset Resilience Ratio
Sunmax Biotechnology Co Ltd (4728) has an Asset Resilience Ratio of 10.53% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Sunmax Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Sunmax Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$200.00 Million | 10.53% |
| Total Liquid Assets | NT$200.00 Million | 10.53% |
Asset Resilience Insights
- Moderate Liquidity: Sunmax Biotechnology Co Ltd has 10.53% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Sunmax Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sunmax Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Sunmax Biotechnology Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Sunmax Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.86% | NT$90.00 Million | NT$1.85 Billion | -0.10pp |
| 2023-12-31 | 4.96% | NT$107.10 Million | NT$2.16 Billion | -7.72pp |
| 2022-12-31 | 12.68% | NT$227.37 Million | NT$1.79 Billion | +7.50pp |
| 2021-12-31 | 5.17% | NT$76.79 Million | NT$1.48 Billion | -4.43pp |
| 2020-12-31 | 9.60% | NT$131.01 Million | NT$1.36 Billion | -3.38pp |
| 2019-12-31 | 12.98% | NT$144.42 Million | NT$1.11 Billion | -14.99pp |
| 2018-12-31 | 27.97% | NT$211.95 Million | NT$757.89 Million | +8.08pp |
| 2017-12-31 | 19.88% | NT$131.40 Million | NT$660.92 Million | +17.70pp |
| 2016-12-31 | 2.19% | NT$13.06 Million | NT$597.49 Million | -- |